-
Study aim
-
Evaluation of probiotic administration on immune responses and clinical manifestations in patients with systemic lupus erythematosus
-
Design
-
Clinical trial with control group, community-based, with parallel groups, thriple blind, randomized
-
Settings and conduct
-
Before and 4 months after the intervention, 5 cc of blood is taken from the brachial vein of patients for examinations, real time PCR and preparation of serum for ELISA test.In monthly visits, in addition to the activity of the disease, a checklist of the number and dose of drugs used by patients in both groups is recorded to be compared at the end of the study and the confusing points of treatment changes are removed from the study.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: All patients with systemic lupus erythematosus between the ages of 18 to 45 years living in Mashhad and surrounding cities with a SLEDAI score between 4.5 to 10.Be willing to cooperate in the project. Exclusion criteria: Patients who are not satisfied to continue cooperation.
-
Intervention groups
-
Patients are divided into two equal groups (23 people in each group) using block block randomization method and in one group, in addition to common treatments for lupus, oral probiotic Lact 2 Plus is prescribed, and in the other group, in addition to common treatments, A placebo is prescribed.
-
Main outcome variables
-
Evaluation of IL17 protein levels, Evaluation of FOXP3, T-bet, GATA-3 and ROR γt transcription factor gene expression by SYBR Green real-time RT-PCR at the beginning of the process, four months after the course